Newamsterdam Pharma Company Nv (NAMS) Technical Analysis
$23.60▲1.03%
Market is closed - opens 7 PM, 14 Mar 2025
Insights
- Newamsterdam Pharma Company Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Newamsterdam Pharma Company Nv stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Newamsterdam Pharma Company Nv stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Newamsterdam Pharma Company Nv stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 61.01 | Sell |
Stochastic | 87.66, 85.44 | Neutral |
Ultimate Oscillator | 64.34 | Neutral |
Stochastic Relative Strength Index | 88.45, 92.62 | Sell |
Moving Average Convergence Divergence | 0.55, 0.03 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 22.36 | Buy |
20 | 20.71 | Sell |
50 | 22.22 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 22.35 | Buy |
20 | 21.66 | Sell |
50 | 21.7 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 22.23 | Buy |
20 | 21.2 | Buy |
50 | 22.2 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 23.47 | Buy |
20 | 22.16 | Buy |
50 | 21.5 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 23.94 | Buy |
20 | 23.21 | Buy |
50 | 21.06 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 25.45 |
Resistance L2 | 24.67 |
Resistance L1 | 23.77 |
Pivot Point | 22.99 |
Support L1 | 22.1 |
Support L2 | 21.32 |
Support L3 | 20.42 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.